Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) versus salmeterol xinafoate / f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QVM149 (Indacaterol acetate / glycopyrronium bromide / mometasone furoate)
• Salmeterol xinafoate / fluticasone propionate (Salmeterol xinafoate / fluticasone propionate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 3 | Status: NOT_YET_RECRUITING